The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.

① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.

cls.cnFeb 28 10:46 ET

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

The main line of Technology continues to evolve, and the AI computing power sector is expected to gain strength.

Track the entire lifecycle of the main Sector.

cls.cnFeb 26 20:26 ET

Will pay over 30 million equity dispute amounts. Getein Biotech, Inc has issued multiple lawsuit announcements in the past four months | Brief announcement.

① Getein Biotech, Inc and nine minority shareholders of Jingchuan Diagnostics, including Wuhan Boruihong, have received a final judgment in their equity acquisition dispute. ② According to the judgment, Getein Biotech, Inc will pay over 30 million yuan for the acquisition.

cls.cnFeb 26 09:28 ET

Sales of two centralized procurement products have increased significantly. Sino Medical Sciences Technology Inc. is expected to turn a profit in 2024, and the Brackets are anticipated to obtain registration certification within the year.

① The company's new spiny balloon product also started large-scale sales in 2024, but the admission rate for the spiny balloon is lower than expected; ② The subsidiary Sinopharm ShenChang officially began production in the second quarter of 2023. Due to the short period of production, the capacity utilization rate is relatively low, resulting in higher fixed costs allocated per unit product.

cls.cnFeb 26 08:29 ET

To extend its Industry Chain layout, Sansure Biotech Inc. intends to acquire 54% equity in Hong'an Jiyuan, which has not yet turned a profit.

①Sansure Biotech Inc. stated that the company values the product's ease of operation, good stability, and high cost performance of Hong'an Jiyuan, making it suitable for projects in grassroots Medical Institutions; ②Since the launch of related products from Hong'an Jiyuan in 2024, thousands of blood analyzers have been installed in various provinces across the country within one year.

cls.cnFeb 25 22:29 ET